Cocaine, methamphetamine, and prescription stimulants affect the brain in powerful ways. This guide explains what stimulant use disorder is, why there are no FDA-approved medications, and what treatments actually work.
Stimulants include cocaine, methamphetamine, and prescription amphetamines (Adderall, Vyvanse) and methylphenidate (Ritalin). Despite differences in how they are used, they share a common mechanism: a massive, rapid surge in brain dopamine.
Under normal circumstances, the brain releases dopamine in response to rewarding experiences. Stimulants bypass this process and flood dopamine pathways with levels far beyond what natural rewards can produce. This creates an intense but brief euphoria, followed by a sharp drop in dopamine as the drug clears. Over time, the brain compensates by reducing its own dopamine output and decreasing the number of dopamine receptors, making everything, including food, relationships, and accomplishments, feel flat by comparison.
This is why withdrawal feels so devastating. The crash after stimulant use is not a matter of willpower or weakness. It reflects a brain that has been chemically reorganized and now struggles to generate normal reward signals without the drug.
Stimulant use disorder is diagnosed based on a pattern of use that causes significant impairment or distress: loss of control over use, continued use despite consequences, cravings, and withdrawal. Severity ranges from mild to severe depending on how many diagnostic criteria are met.
"The brain changes caused by repeated stimulant use are real, measurable, and in many cases persistent. Understanding them as medical phenomena rather than moral failures is the foundation of effective treatment."
William Bundy Jr., PharmD | ToxiPharm LLCCocaine metabolites (benzoylecgonine) are detectable by immunoassay for approximately 2 to 4 days after single use, and up to 10 or more days with heavy or chronic use. Methamphetamine and prescription amphetamines (Adderall, Vyvanse) are detected by the same amphetamine immunoassay. A positive amphetamine screen does not distinguish between illicit methamphetamine and a legitimate prescription stimulant without confirmatory testing and clinical context.
Unlike opioid use disorder and alcohol use disorder, stimulant use disorder currently has no pharmacotherapy approved by the FDA. This gap is often misunderstood in ways that directly harm people seeking treatment.
The absence of an FDA-approved medication does not mean that stimulant use disorder is untreatable, that people just need to "want it more," or that the only path is willpower alone. These conclusions are wrong, and they reflect a misreading of what "no approved medication" actually means.
Why the gap exists is partly about neurobiology. Opioid use disorder and alcohol use disorder both have well-characterized receptor targets that medications can modulate predictably. Stimulant use disorder involves a more complex disruption of dopamine circuits, and identifying a single pharmacological lever that improves outcomes without significant risk has proved difficult. Clinical trials have been challenging to design and run, and the heterogeneity of the stimulant-using population (cocaine vs. methamphetamine; occasional vs. heavy chronic use) makes regulatory approval harder to achieve.
Research is ongoing. NIDA and the NIH HEAL (Helping to End Addiction Long-term) Initiative are actively funding trials. The combination of injectable naltrexone plus bupropion received a breakthrough therapy designation from FDA for methamphetamine use disorder following a 2021 trial showing modest but significant benefit. This is the closest the field has come to an approved pharmacotherapy.
Behavioral interventions, particularly contingency management, have strong and consistent evidence for reducing stimulant use and supporting recovery. The absence of pharmacotherapy shifts the primary treatment modality, it does not eliminate effective options.
Stimulant use disorder involves measurable changes in brain structure and function, including reduced dopamine receptor density and impaired prefrontal regulation of impulse control. These changes do not resolve on their own simply through resolve. They respond to treatment.
Because pharmacotherapy is not yet available, the evidence base for stimulant use disorder centers on structured behavioral interventions. These are not a consolation prize. Contingency management in particular has a larger and more consistent evidence base than many approved medications in other conditions.
CM uses positive reinforcement, typically vouchers or small prizes earned for negative drug tests and consistent treatment attendance, to reshape behavior. Multiple randomized controlled trials show it reduces stimulant use, improves retention in treatment, and extends the duration of abstinence. The VA system, SAMHSA, and ASAM all endorse CM as a first-line approach. The primary barrier is not efficacy but access: many programs do not yet offer it, and insurance coverage has historically been inconsistent, though this is improving.
CBT for stimulant use disorder focuses on identifying triggers for use, developing coping strategies for cravings, and building skills to manage high-risk situations. It is typically delivered in individual or group sessions over 12 to 16 weeks. Evidence supports its effectiveness both alone and in combination with CM. CBT skills persist after treatment ends, which supports long-term outcomes.
MET is a client-centered, directive counseling approach designed to strengthen motivation for change. It is particularly useful for people who are ambivalent about treatment or who have had previous unsuccessful attempts. MET is often delivered in 2 to 4 sessions and is frequently combined with CBT.
Cocaine Anonymous (CA) and Crystal Meth Anonymous (CMA) are peer-support fellowships modeled on the 12-step framework. While they lack the controlled-trial evidence base of CM or CBT, they provide community, accountability, and ongoing support that many people find essential for sustained recovery. Peer support is most effective as a complement to structured treatment, not a replacement for it.
Contingency management aligns closely with drug court principles: structured accountability, reinforcement for compliance, and consequences for violations. Programs that incorporate CM-style incentives for negative tests and attendance often see better outcomes with stimulant-using participants than programs relying on sanctions alone.
Off-label does not mean experimental or unsafe. It means the medication has not completed the FDA approval pathway for this specific indication. Several options have enough trial data to support clinical use in selected patients, particularly when behavioral treatment alone has not been sufficient.
A dopamine and norepinephrine reuptake inhibitor. Has the most trial data for methamphetamine use disorder, particularly in combination with injectable naltrexone (the ADAPT-2 trial). Most beneficial in people with lower to moderate severity use. Also treats depression, which commonly co-occurs. Not controlled; prescribable by any provider.
An opioid antagonist. Studied for cocaine and methamphetamine use disorder, particularly the monthly injectable formulation. The combination of injectable naltrexone plus bupropion received FDA Breakthrough Therapy designation for methamphetamine use disorder in 2021. Not controlled; prescribable by any provider. Cannot be taken with opioids.
An antidepressant with noradrenergic and serotonergic activity. Randomized trial data support its use for methamphetamine use disorder, particularly in men who have sex with men. Also helps with sleep and anxiety during early recovery. Not controlled.
An over-the-counter antioxidant that restores glutamate balance in the nucleus accumbens. Some evidence for reducing cravings in cocaine use disorder. Low cost, widely available, and well-tolerated. Evidence is preliminary; best viewed as adjunctive rather than primary treatment.
An anticonvulsant that modulates glutamate and GABA activity. Some trial evidence for cocaine use disorder. Cognitive side effects (word-finding difficulty, mental slowing) limit tolerability for many people. Must be tapered slowly before stopping. Avoid in pregnancy.
None of these off-label medications will produce a positive result on standard drug tests for cocaine or methamphetamine. However, if a person is prescribed a stimulant medication (bupropion is not a stimulant, but Adderall, Vyvanse, or Ritalin are), that prescription will produce a positive amphetamine immunoassay result. Confirmatory testing and prescriber verification are required before drawing clinical or legal conclusions from a positive amphetamine screen.
Stimulant withdrawal is not medically dangerous in the way alcohol or opioid withdrawal can be, but it is genuinely difficult. Understanding the timeline helps people in treatment, their families, and supervision programs set realistic expectations.
Intense fatigue, prolonged sleep, depression, increased appetite, and profound anhedonia. The person may sleep for 18 to 24 hours. This is the brain's acute response to the sudden absence of stimulant-driven dopamine. It is not a choice and should not be confused with drug-seeking behavior or noncompliance.
Improving energy but persistent low mood, irritability, sleep disturbance, and difficulty concentrating. Cravings begin to emerge as the crash phase resolves. Engagement with treatment and peer support during this window is critical.
Acute withdrawal resolves but cravings often peak as the person re-engages with daily life and encounters cue-associated triggers. This is the highest-risk window for return to use. Structured support, contingency management, and coping skills from CBT are most impactful here.
Many people experience intermittent mood instability, cognitive fog, fatigue, and cue-triggered cravings for months after stopping. This post-acute withdrawal syndrome (PAWS) reflects the brain's slow restoration of normal dopamine function. It is real, it is neurological, and it responds to continued treatment engagement.
Mood, energy, and cognitive function gradually improve. Cue-triggered cravings can still occur, sometimes for years, particularly with methamphetamine. Ongoing peer support and behavioral skills remain protective. Recovery is not a fixed endpoint but a sustained process.
A note on ADHD medications and drug testing
Persons prescribed amphetamine-based ADHD medications (Adderall, Vyvanse, Dexedrine) or methylphenidate (Ritalin, Concerta) will produce positive results on standard amphetamine immunoassays. This is expected, appropriate, and not evidence of illicit stimulant use. Some providers prefer non-stimulant ADHD medications (atomoxetine, guanfacine, viloxazine) during early recovery to avoid interpretive complexity in monitored settings. Any positive amphetamine screen should be confirmed and evaluated in context before clinical or legal conclusions are drawn.
Find support and treatment
Free, confidential treatment referrals for substance use disorders. Available 24/7 in English and Spanish.
12-step peer support fellowship for people affected by methamphetamine use. Meetings available in person and online.
crystalmeth.org →12-step peer support fellowship for cocaine and other stimulant use disorders. Meetings available worldwide.
ca.org →Locate nearby treatment programs, including those offering contingency management, by zip code.
Find Treatment →New to this series? Guide 01 covers the biology of addiction and why the brain makes stopping so hard.
Read Guide 01 →Clinical Reference
For a comprehensive patient-facing overview of stimulant use disorder and its treatment, see the ASAM Stimulant Use Disorder Patient Guide, published by the American Society of Addiction Medicine and Guideline Central.
This guide is for general educational purposes only and does not constitute medical advice. If you are experiencing a medical emergency, call 911. For substance use support, contact SAMHSA at 1-800-662-4357.
Educational content is for general informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for guidance specific to your situation.